Related Experiment Videos

Insulin pump treatment of childhood type 1 diabetes

Stuart A Weinzimer1, Kristin A Sikes, Amy T Steffen

  • 1Department of Pediatrics, Yale University School of Medicine, PO Box 208064, New Haven, CT 06520-8064, USA. stuart.weinzimer@yale.edu

Pediatric Clinics of North America
|November 23, 2005
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII) effectively manages type 1 diabetes in children and adolescents. This advanced therapy improves blood sugar control and reduces hypoglycemia risks without compromising safety or quality of life.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Type 1 diabetes mellitus (T1DM) treatment in pediatric populations aims for glycemic control, hypoglycemia prevention, enhanced quality of life, and delayed microvascular complications.
  • Continuous subcutaneous insulin infusion (CSII) offers a potential therapeutic strategy for achieving these multifaceted goals across all pediatric age groups.

Purpose of the Study:

  • To review the safety and efficacy of CSII in children and adolescents with T1DM.
  • To evaluate CSII's role in achieving treatment objectives for pediatric T1DM patients.

Main Methods:

  • Review of clinical studies assessing the safety and efficacy of CSII in pediatric populations.
  • Analysis of data regarding glycosylated hemoglobin levels, hypoglycemia frequency, quality of life, and weight changes associated with CSII use.

Main Results:

  • CSII use is associated with reduced glycosylated hemoglobin levels and decreased frequency of severe hypoglycemia in children with T1DM.
  • These benefits were observed without adverse effects on safety, quality of life, or significant weight gain.
  • Improvements in pump technology and the availability of new insulin analogs enhance CSII's effectiveness.

Conclusions:

  • CSII is a safe and effective treatment option for children and adolescents with T1DM.
  • CSII, especially when combined with modern insulin analogs and pump technology, aids in achieving optimal glycemic control and improving patient outcomes.
  • The review supports the continued use and investigation of CSII in pediatric diabetes care.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...